Cited by 115Bipolar Disorder and TreatmentSchizophrenia research and treatmentPersonality Disorders and Psychopathology

Lithium vs. valproate vs. olanzapine vs. quetiapine as maintenance monotherapy for bipolar disorder: a population‐based UK cohort study using electronic health records

Open access
Hayes, Joseph F., Marston, Louise, Walters, Kate, Geddes, John R., King, Michael, Osborn, David P.J.·2016·World Psychiatry

Abstract

It is unclear which maintenance treatment for bipolar disorder is superior in clinical practice. Randomized controlled head‐to‐head trials of available drugs either do not exist or are inconclusive. We aimed to compare rates of monotherapy treatment failure in individuals prescribed lithium, valproate, olanzapine or quetiapine by a population‐based cohort study using electronic health records. 5,089 patients with bipolar disorder were prescribed lithium (N=1,505), valproate (N=1,173) olanzapine (N=1,366) or quetiapine (N=1,075) as monotherapy. Treatment failure was defined as time to stopping medication or add‐on of another mood stabilizer, antipsychotic, antidepressant or benzodiazepine. In unadjusted analyses, the duration of successful monotherapy was longest in individuals treated with lithium. Treatment failure had occurred in 75% of those prescribed lithium by 2.05 years (95% CI: 1.63‐2.51), compared to 0.76 years (95% CI: 0.64‐0.84) for those prescribed quetiapine, 0.98 years (95% CI: 0.84‐1.18) for those prescribed valproate, and 1.13 years for those prescribed olanzapine (95% CI: 1.00‐1.31). Lithium's superiority remained in a propensity score matched analysis; when treatment failure was defined as stopping medication or add‐on of a mood stabilizer or antipsychotic; and when treatment failure was restricted to more than three months after commencing the study drug. Lithium appears to be more successful as monotherapy maintenance treatment than valproate, olanzapine or quetiapine. Lithium is often avoided because of its side effect profile, but alternative treatments may reduce the time to being prescribed more than one drug, with potential additive side effects of these treatments.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/wps.20298

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 40 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Blak B, Thompson M, Bourke A. National representativeness and data quality of The Health Improvement Network (THIN) database of primary care infor- mation for epidemiological research. Presented at the 9th Annual Conference of the UK Federation of Primary Care Research, Liverpool, November 2006.
  2. Lis Y, Mann RD. The VAMP Research multi-purpose database in the UK. J Clin Epidemiol 1995;48:431-43.

Cited by

Sorted by citations

Authors
Hayes, J. F., Marston, L., Walters, K., Geddes, J. R., King, M., & Osborn, D. P. J.
Affiliations
  • University College London (GB)
  • University of Oxford (GB)
Venue
World Psychiatry
Publisher
Wiley
Published
2016-02
Volume
15
Issue
1
Pages
53-58
ISSN
  • 1723-8617 (ISSN-L)
  • 2051-5545
OpenAlex
W2275840112
Cited by
115
References
40
Citations by year
2026: 2 · 2025: 5 · 2024: 11 · 2023: 8 · 2022: 7 · 2021: 13 · 2020: 13 · 2019: 14 · 2018: 18 · 2017: 18 · 2016: 6
FWCI
16.37
Type
journal article
Language
en
Open access
Locations
  • World Psychiatry (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
Medical Research Council Population Health Scientist Fellowship (MR/K021362/1)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
  • Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
Keywords
bipolar disorder, lithium, valproic acid, olanzapine, quetiapine, maintenance monotherapy, treatment failure, mood stabilizers, antipsychotic drugs, drug switching, propensity score matching

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review